Kurzfassung

A randomized, double-blind, placebo-controlled phase III study of the Bruton's Tyrosine Kinase (BTK) inhibitor, PCI-32765 (Ibrutinib), in combination with Bendamustine and Rituximab (BR) in subjects with newly diagnosed mantle cell lymphoma